The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Patients’ experience and physicians strategies for selection of anthracyclines and taxanes sequential treatment in adjuvant breast cancer: The Violayne prospective multicenter survey.
M. Namer
Consultant or Advisory Role - Hospira
J. Gligorov
Consultant or Advisory Role - Hospira
E. Antoine
Consultant or Advisory Role - Hospira
M. Spielmann
Consultant or Advisory Role - Hospira
T. Facchini
Consultant or Advisory Role - Hospira